

WHAT IS CLAIMED IS:

1. A method for treating pulmonary hypertension, comprising administering to a subject in need thereof treprostinil or treprostinil derivative, or a pharmaceutically acceptable salt thereof by a metered dose inhaler.
2. The method of claim 1, wherein said metered dose inhaler is a pressured metered dose inhaler.
3. The method of claim 1, wherein said metered dose inhaler is a dry powder inhaler.
4. The method of claim 1, wherein said metered dose inhaler is a soft mist inhaler.
5. The method of claim 4, wherein said treprostinil is formulated in said inhaler as a solution, wherein a solvent of the solution comprises water, ethanol or a mixture thereof.
6. The method of claim 5, wherein a concentration of the treprostinil in the solution ranges from about 500  $\mu\text{g/ml}$  to about 2500  $\mu\text{g/ml}$ .
7. The method of claim 6, wherein the concentration of the treprostinil in the solution ranges from about 1000  $\mu\text{g/ml}$  to about 2000  $\mu\text{g/ml}$ .
8. The method of claim 1, wherein a dose of the treprostinil administered during a single event ranges from about 15  $\mu\text{g}$  to about 100  $\mu\text{g}$  of the treprostinil.
9. The method of claim 8, wherein the dose ranges from about 30  $\mu\text{g}$  to about 90  $\mu\text{g}$  of the treprostinil.

10. The method of claim 1, wherein said administering does not have a systemic side effect on said subject, wherein the systemic side effect is selected from the group consisting of headache, flush, nausea, and dizziness.

11. The method of claim 1, wherein said administering does not disrupt gas exchange in said subject.

12. The method of claim 1, wherein said administering does change heart rate of said subject.

13. The method of claim 1, wherein said administering does not affect systemic arterial pressure and systemic arterial resistance.

14. The method of claim 1, wherein said administering comprises a limited number of breaths by said subject.

15. The method of claim 1, wherein said administering lasts less than 5 minutes.

16. The method of claim 1, wherein said administering lasts less than 1 minute.

17. The method of claim 1, wherein said subject is a human being.

18. The method of claim 1, further comprising administering to said subject at least one supplementary agent selected from the group consisting of diltiazem, amlodipine, nifedipine, sildenafil, tadalafil, vardenafil, bosentan, sitaxsentan, ambrisentan, prostacyclin, iloprost, beraprost and pharmaceutically acceptable salts thereof.

19. A method of delivering to a subject in need thereof a therapeutically effective amount of treprostinil, or treprostinil derivative or a pharmaceutically acceptable salt thereof comprising administering to the subject the therapeutically effective amount of the treprostinil or treprostinil derivative or a pharmaceutically acceptable salt thereof using a metered dose inhaler.

20. The method of claim 19, wherein said metered dose inhaler is a pressured metered dose inhaler.

21. The method of claim 19, wherein said metered dose inhaler is a dry powder inhaler.

22. The method of claim 19, wherein said metered dose inhaler is a soft mist inhaler.

23. The method of claim 22, wherein said treprostinil is formulated in the metered dose inhaler as a solution, wherein a solvent of the solution comprises water, ethanol or a mixture thereof.

24. The method of claim 23, wherein a concentration of the treprostinil in the solution ranges from about 500  $\mu\text{g/ml}$  to about 2500  $\mu\text{g/ml}$ .

25. The method of claim 24, wherein the concentration of the treprostinil in the solution ranges from about 1000  $\mu\text{g/ml}$  to about 2000  $\mu\text{g/ml}$ .

26. The method of claim 19, wherein a dose of the treprostinil administered during a single event ranges from about 15  $\mu\text{g}$  to about 100  $\mu\text{g}$  of the treprostinil.

27. The method of claim 26, wherein the dose ranges from about 30  $\mu\text{g}$  to about 90  $\mu\text{g}$  of the treprostinil.

28. The method of claim 19, wherein said administering does not have a systemic side effect on said subject, wherein the systemic side effect is selected from the group consisting of headache, flush, nausea, and dizziness.

29. The method of claim 19, wherein said administering does not disrupt gas exchange in said subject.

30. The method of claim 19, wherein said administering does change heart rate of said subject.

31. The method of claim 19, wherein said administering does not affect systemic arterial pressure and systemic arterial resistance.

32. The method of claim 19, wherein said administering comprises a limited number of breaths by said subject.

33. The method of claim 19, wherein said administering lasts less than 5 minutes.

34. The method of claim 19, wherein said administering lasts less than 1 minute.

35. The method of claim 19, wherein said subject is a human being.

36. A kit for treating pulmonary hypertension, comprising (i) a metered dose inhaler containing a pharmaceutical formulation comprising treprostinil or

treprostinil derivative, or a pharmaceutically acceptable salt thereof; and (ii) instructions for use of in treating pulmonary hypertension.

37. The kit of claim 36, wherein said metered dose inhaler is a pressured metered dose inhaler.

38. The kit of claim 36, wherein said metered dose inhaler is a dry powder inhaler.

39. The kit of claim 36, wherein said metered dose inhaler is a soft mist inhaler.

40. The kit of claim 39, wherein said formulation further comprises water, ethanol or a mixture thereof.

41. The kit of claim 36, wherein a concentration of the treprostinil in said formulation is from about 500  $\mu\text{g}/\text{ml}$  to about 2500  $\mu\text{g}/\text{ml}$ .

42. The kit of claim 41, wherein said concentration is from about 1000  $\mu\text{g}/\text{ml}$  to about 2000  $\mu\text{g}/\text{ml}$ .

43. The kit of claim 36, further comprising an effective amount of at least one supplementary agent selected from the group consisting of diltiazem, amlodipine, nifedipine, sildenafil, tadalafil, vardenafil, bosentan, sitaxsentan, ambrisentan, prostacyclin, iloprost, beraprost and pharmaceutically acceptable salts thereof.

44. A kit comprising a metered dose inhaler containing a pharmaceutical formulation comprising treprostinil or treprostinil derivative, or a pharmaceutically acceptable salt thereof.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.